Patent details

EP2827862 Title: FORMULATIONS OF BENDAMUSTINE

Basic Information

Publication number:
EP2827862
PCT Application Number:
US2013032289
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP137649893
PCT Publication Number:
WO2013142358
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
FORMULATIONS OF BENDAMUSTINE
French Title of Invention:
FORMULATIONS DE BENDAMUSTINE
German Title of Invention:
FORMULIERUNGEN AUS BENDAMUSTIN
SPC Number:

Dates

Filing date:
15/03/2013
Grant date:
27/12/2023
EP Publication Date:
28/01/2015
PCT Publication Date:
26/09/2013
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
27/12/2023
EP B1 Publication Date:
27/12/2023
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
15/03/2024
Expiration date:
15/03/2033
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
20/12/2023
 
 

Name:
Eagle Pharmaceuticals, Inc.
Address:
50 Tice Boulevard Suite 315, Woodcliff Lake, NJ 07677, United States (US)

Inventor

Name:
SUNDARAM, Srikanth
Address:
United States (US)

Priority

1

Priority Number:
201261613173 P
Priority Date:
20/03/2012
Priority Country:
United States (US)

2

Priority Number:
201261669889 P
Priority Date:
10/07/2012
Priority Country:
United States (US)

Classification

IPC classification:
A61K 31/4184; A61K 47/10; A61K 47/20; A61K 9/00;

Publication

European Patent Bulletin

1

Issue number:
202352
Publication date:
27/12/2023
Description:
Grant (B1)

2

Issue number:
202404
Publication date:
24/01/2024
Description:
Application number/publication number of the divisional application (Art. 76) changed

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages